Mira Pharmaceuticals (MIRA) Current Deferred Tax Assets (2022 - 2023)

Mira Pharmaceuticals (MIRA) posted Current Deferred Tax Assets of $353372.0 for Q2 2023, up 146.38% sequentially from $143427.0 in Q4 2022.

Mira Pharmaceuticals (MIRA) Current Deferred Tax Assets (2022 - 2023) Analysis & Trends

Mira Pharmaceuticals (MIRA) has 2 years of Current Deferred Tax Assets data on file, last reported at $353372.0 in Q2 2023.

Quarterly Current Deferred Tax Assets changed N/A year-over-year to $353372.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $353372.0 (changed N/A YoY) and the FY2022 annual result came in at $143427.0, changed N/A from the prior year.
Current Deferred Tax Assets climbed to $353372.0 in Q2 2023 per MIRA's latest filing, from $143427.0 in the prior quarter.
The five-year high for Current Deferred Tax Assets was $353372.0 in Q2 2023, with the low at $143427.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Mira Pharmaceuticals	22.51 Mn	11.48 Mn	-

Download Data